Date Time
Gene therapy appears more cost effective than current treatments for severe hemophilia B
From left: Co-senior author Nickhill Bhakta, M.D., of St. Jude Global Pediatric Medicine; co-senior author Ulrike Reiss, M.D., of the St. Jude Department of Hematology; and first and corresponding author Nancy Bolous, M.D., of St. Jude Global Pediatric Medicine, provide research on the costs of hemophilia gene therapy now in development.
A St. Jude Children’s Research Hospital analysis found a major gap between the cost to manufacture and distribute hemophilia B gene therapy and the $2 million-plus price reportedly under consideration for hemophilia gene therapy now in development.